- Blood plasma proteome-wide association study implicates novel
- 2 proteins in the pathogenesis of multiple cardiovascular diseases
- 4 Jia-Hao Wang^{1#}, Shan-Shan Dong^{1#}, Hao-An Wang¹, Shao-Shan Liu¹, Xiaoyi Ma²,
- 5 Ren-Jie Zhu¹, Wei Shi¹, Hao Wu¹, Ke Yu¹, Tian-Pei Zhang¹, Cong-Ru Wang¹, Yan
- 6 Guo^{1*}, Tie-Lin Yang^{1*}

3

7

- 8 ¹Key Laboratory of Biomedical Information Engineering of Ministry of Education,
- 9 Key Laboratory of Biology Multiomics and Diseases in Shaanxi Province Higher
- 10 Education Institutions, Biomedical Informatics & Genomics Center, School of Life
- 11 Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China,
- 12 710049

15

18

22

- ²Department of Biostatistics, School of Public Health and Health Professions,
- 14 The State University of New York at Buffalo
- 16 #These authors contributed equally to this study.
- 17 *Corresponding authors
- 19 Address Correspondence to:
- 20 Dr. Tie-Lin Yang and Dr. Yan Guo
- 21 E-mail: yangtielin@xjtu.edu.cn, guoyan253@xjtu.edu.cn

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Abstract Cardiovascular diseases (CVD) are the leading cause of global mortality, but current treatments are only effective in a subset of individuals. To identify new potential treatment targets, we present here the first PWAS for 26 CVDs using plasma proteomics data of the largest cohort to date (53,022 individuals from the UK Biobank Pharma Proteomics Project (UKB-PPP) project). The GWAS summary data for 26 CVDs spanning 3 categories (16 cardiac diseases, 5 venous diseases, 5 cerebrovascular diseases, up to 1,308,460 individuals). We also conducted replication analyses leveraging two other independent human plasma proteomics datasets, encompassing 7,213 participants from the Atherosclerosis Risk in Communities (ARIC) study and 3,301 individuals from the INTERVAL study. We identified 94 genes that are consistent with being causal in CVD, acting via their cis-regulated plasma protein abundance. 34 of 45 genes were replicated in at least one of the replication datasets. 41 of the 94 genes are novel genes not implicated in original GWAS. 91.48% (86/94) proteins are category-specific, only two proteins (ABO, PROCR) were associated with diseases in all three CVD categories. Longitudinal analysis revealed that 37 proteins exhibit stable expression in plasma. In addition, PBMC scRNA-seq data analysis showed that 23 of the 94 genes were stably expressed in CD14+ monocytes, implicating their potential utility as biomarkers for CVD disease status. Drug repurposing analyses showed that 39 drugs targeting 23 genes for treating diseases from other systems might be considered in further research.

In conclusion, our findings provide new insights into the pathogenic mechanisms of

CVD and offering promising targets for further mechanistic and therapeutic studies.

Keywords: CVD; Human blood plasma proteomes; Causal proteins; PWAS

The pathogenic mechanisms of CVD and offering promising targets for further mechanistic and therapeutic studies.

53 Introduction 54 Cardiovascular diseases (CVD) are a group of disorders of the heart and blood vessels. As the leading global cause of mortality ^{1, 2}, CVD took an estimated 17.9 million lives 55 in 2019, accounting for 32% of all deaths worldwide³. In clinical practice, there are 56 57 some commonly used treatments for CVD, such as the use of statins to reduce 58 cardiovascular morbidity and mortality. However, current treatments are not suitable for all patients and have certain risks of side effects⁴. Therefore, there is an urgent and 59 critical need for new therapeutic targets for CVD⁵. 60 61 62 Proteins, as the final products of gene expression, are the main functional components of biological processes⁶. In addition, most therapeutic agents target proteins⁷. 63 64 Therefore, understanding their relationship with diseases is crucial for effective treatments⁸⁻¹¹. However, direct observational studies linking protein abundance to 65 phenotypes can be confounded or represent reverse causation¹². Proteome-wide 66 67 association study (PWAS) is a powerful strategy to solve this problem. It uses single-68 nucleotide polymorphisms (SNPs) to genetically impute proteins and relate them to 69 genome wide association study (GWAS) summary statistics of a trait to provide evidence of causality^{13, 14}. The genetic models are restricted to the cis-region of the 70 71 protein, reducing the risk of confounding by horizontal pleiotropy (independent of the protein). Further summary data-based Mendelian randomization (SMR)¹⁵ or 72 colocalization analyses¹⁶ can be used to identify genes contribute to disease 73

pathogenesis through modulating protein abundance. This integrative analytical

74

approach has been employed to identify novel potential therapeutic targets for neurological disorders 13, 14, 17-19 using brain proteomics data. However, PWAS for CVD is still limited. Using plasma proteomics data of the largest cohort to date (53,022 individuals from the UK Biobank Pharma Proteomics Project (UKB-PPP) project²⁰), we present here the first PWAS for multiple CVDs. The study design is shown in Figure 1. We applied the above analytic approaches to the discovery dataset consisting of human plasma proteomic and genetic data from UKB-PPP²⁰ and the GWAS of 26 CVDs spanning 3 categories (16 cardiac diseases, N = 234,829~1,030,836; 5 venous diseases, N = $388,830 \sim 484,598$; 5 cerebrovascular diseases, N = $484,598 \sim 1,308,460$)²¹⁻²⁶. Additionally, we conducted replication analyses leveraging two independent human plasma proteomics datasets^{27, 28}, encompassing 7,213 participants from the Atherosclerosis Risk in Communities (ARIC) study and 3,301 individuals from the INTERVAL study, to ensure robustness and reproducibility. For functional interpretation of the identified proteins, enrichment analyses were performed to detect the pathways associated with CVD. Longitudinal stability analysis at plasma and celltype level was used to assess the expression stability of the proteins. We also pharmacologically annotate the proteins of interest with approved drugs to assess their feasibility as treatment targets.

Results

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

Discovery PWAS of multiple CVDs We generated the human blood plasma proteome model based on 53,022 UKB-PPP²⁰ participants. The initial proteomes data include total 2,923 proteins. After quality control, 1,715 proteins with significant SNP-based heritability (P < 0.05, $h^2 > 0$), were used for PWAS. The correlation R² between the model's predictive power and heritability for each gene was 0.88 (Supplementary Figure S1), supporting the accuracy of our protein estimation model. The plasma proteome model results were integrated with the 26 CVD GWAS data using the FUSION pipeline²⁹. Detail information of the 26 GWAS datasets is shown in Supplementary Table S1. We performed genetic correlation analysis and the results showed that diseases belong to the same category are usually with higher correlation (Supplementary Figure S2). As shown in Supplementary Table S2, we identified 341 significant protein-CVD pairs of associations after multiple testing corrections ($P < 2.92 \times 10^{-5}$, 0.05/1,715 proteins) (Fig 2A). Among these associations, 87 genes are located within 1 Mb of each other. With the goal of identifying multiple independent associations, we performed conditional analyses using a regression with summary statistics approach ²⁷. 27 pairs of associations no longer significant associations were removed (Supplementary Table S3). Finally, we obtained 314 independent and significant PWAS association signals, including 155 unique proteins associated with CVD. The

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

number of associated genes for each phenotype is shown in Figure 2B. Taking heart failure as an example, PWAS identified 48 proteins associated with it (Fig 2B). 18 genes from 7 loci were subjected to conditional analysis. Six genes (SORTI, SHISA5, PDE5A, PGF, FURIN, DDT) were no longer significant after conditional analysis and were removed from subsequent analyses (Fig 2C). Finally, we obtained 42 genes associated with heart failure. Replication PWAS using the proteomics data from ARIC and INTERVAL For the 155 proteins identified from the discovery dataset, 75 were detected in the at least one of the replication proteomic datasets. The number of detected proteins in the ARIC and INTERVAL project was 64 and 50, respectively. For these proteins, we incorporated their previously built human plasma protein models from the FUSION website²⁹ and the CVD GWAS datasets to perform replication PWAS. In the ARIC dataset, the results showed that 46 proteins were associated with CVD (P $< 7.81 \times 10^{-4}$, 0.05/64). As for the INTERVAL dataset, the number of successfully replicated proteins was 37 ($P < 1.00 \times 10^{-3}$, 0.05/50). As shown in supplementary Table S4, the significant association of 55 proteins (73.33%, 55/75) were replicated in at least one dataset with the same effect direction as the discovery PWAS, and 23 proteins were replicated in both datasets.

Causal-analysis of the proteins identified by PWAS

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

We employed two independent but supplementary approaches (SMR and colocalization) to further evaluate the causality of the 155 proteins 15, 16 from the UKB-PPP dataset. The SMR and its accompanying heterogeneity in dependent instruments (HEIDI) test was used to test whether PWAS-significant genes were associated with CVD via their cis-regulated protein abundance. The SMR results showed that the cisregulated protein abundance mediates the association between genetic variants and CVD for 125 unique proteins. However, HEIDI results argued against a causal role for 55 genes due to linkage disequilibrium (Supplementary Table S5). Therefore, 70 unique proteins have evidence consistent with a causal role in CVD by SMR/HEIDI. The colocalization test was used to examine the posterior probability for a shared causal variant between a pQTL and CVD GWAS for the PWAS-significant genes. The colocalization analysis identified 74 proteins with shared causal variant between pQTL and CVD GWAS (posterior probability PPH4 ≥ 0.7). We kept proteins with evidence from either SMR or colocalization analysis, and finally a total of 94 proteins were remained for subsequent analysis (Fig 3A, Supplementary Table S5). Combining evidence for replication and results of causality tests, 45 of 94 causal proteins were detected in the at least one of replication proteomic datasets. 75.56% (34/45) proteins were found to be with evidence of both replication and causality (Table 1). There were 28 proteins replicated in the ARIC dataset and 21 proteins replicated in the INTERVAL dataset. In particular, 15 proteins were replicated in both

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

datasets. For example, ABO, F10, IL6R and PROC. Common proteins associated with diseases in three CVD categories 91.49% (86/94) proteins were identified in only one disease category (Fig 3B). Only 2 proteins (ABO, PROCR) were associated with diseases in all three CVD categories. As shown in Figure 3A, ABO showed significant positive associations with multiple diseases from the three categories. PROCR was negatively associated with 2 cardiac diseases and 1 cerebrovascular disease, and positively associated with 2 venous diseases. The inconsistency in association direction might because PROCR is linked to anti-inflammatory and anticoagulant functions³⁰. Novelty of the CVD causal genes To assess the novelty of the 94 potentially causal genes, we checked the lowest pvalues for the SNPs within 2 Mb window of these genes using the summary statistics from the CVD GWAS. We found that 41 genes were not located within 2 Mb of a significant GWAS signal ($P < 5 \times 10^{-8}$), suggesting that these 41 genes are novel genes not implicated in the original GWAS (Fig 3C). 25 of the novel genes were have not been detected in other CVD GWAS either. For example, PROC was found to be associated with venous thromboembolism (Fig 3D top) and COMT was found to be

associated with three cardiac diseases (hypertension, statin medication and angina

pectoris; Supplementary Figure S3). All 26 CVD GWAS data didn't detect their

association with CVD diseases. The rest 16 novel genes were not implicated in the

original GWAS but have been detected in the GWAS of other CVD. For example, our PWAS results showed that FN1 was associated with coronary heart disease and coronary atherosclerosis (Fig3D bottom). The GWAS of these two diseases didn't detect the association signal of this gene, but it was found to be associated with heart failure, myocardial infarction, coronary revascularization, and coronary artery bypass grafting in their GWAS data. Our results further expand the important role of FN1 in multiple cardiac diseases.

Gene ontology enrichment analysis

To further elucidate the molecular mechanisms underlying the 94 identified proteins, we carried out a non-redundant gene ontology (GO) biological processes enrichment analysis using WebGestalt 2024^{31, 32}. The results (Fig 4A) showed that genes associated with cardiac disease enriched in 12 pathways. 58.33% (7/12) of these pathways belong to three categories (immunity/inflammation, lipid-related process, and vessel/blood-related process). Genes associated with venous diseases were found to be significantly enriched in 5 biological pathways, and three of them belong to the vessel/blood-related process, particularly the coagulation process. No significant pathway was detected for the genes associated with cerebrovascular disease due to the limited number of genes.

Protein-protein interactions (PPI) network analysis

To investigate the connectivity for the 94 proteins, we performed network-based

analysis using STRING³³. The minimum required interaction score was 0.4. We constructed a PPI network with 30 nodes and 37 edges, primarily comprising 3 protein communities. (Fig 4B). The proteins associated with cardiac disease are mainly within the network with FN1and APOE as the core proteins. Consistent with pathway enrichment analysis results, these proteins are mostly in the community of immunity/inflammation and lipid-related process. The network of proteins associated with venous disease is mainly driven by 6 proteins (F2, F10, F11, PROC, PROCR and PROS1) involved in blood/vessel-related process, especially in the coagulation processes. The network for venous disease proteins is distinct from that of cardiac disease proteins, and the two networks are connected by F2 and PROS1. Interactions among the proteins associated with cerebrovascular diseases are relatively sparse. Complete information about communities is presented in Supplementary Table S7.

Mouse phenotypic annotation of potential causal genes.

We further evaluated whether 94 proteins were associated with CVD-related phenotype in mouse using the Mouse Genome Informatics (MGI) database³⁴. We performed phenotype enrichment analysis using the Fisher's exact test. Consistent with the pathway enrichment and network analysis results, mutations in genes associated with cardiac diseases are enriched in phenotypes related to immunity/inflammation, lipid-related process, and vessel/blood-related process (Fig 4C). Mutations in genes associated with venous disease are enriched in phenotypes related to vessel/blood-related process (Fig 4C). These results further support the

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

involvement of the identified proteins in CVD pathogenesis. Evaluate longitudinal stability at protein and single-cell level To evaluate the expression stability of the 94 proteins, we performed longitudinal analysis using data using plasma proteomics data and peripheral blood mononuclear cells (PBMC) single cell RNA-seq (scRNA-seq) data from GEO dataset GSE190992. The plasma proteomics data were collected from 6 healthy, non-smoking Caucasian donors over a 10-week period. 44 of the 94 proteins were detected in this dataset. Among them, 84.09% (37/44) proteins exhibit stable expression in plasma (median coefficient of variation < 10%, Fig4 D left). Fluctuations in the plasma levels of these proteins might serve as potential markers of disease status. The PBMC scRNA-seq data were collected weekly from four donors over the course of six weeks. We found 24 genes exhibited stable expression in at least one cell type (median coefficient of variation < 10% in at least one cell type across all donors. Fig4 D right). Notably, 23 of the 24 genes stably expressed in CD14+ monocytes. As per previous studies, monocytes play a crucial role in both local ischemia and inflammatory responses, which are closely linked to the development of cardiovascular diseases³⁵⁻³⁷.

Cell-type specific expression of the CVD causal genes

To investigate whether these genes show distinct enrich across different cell types, we utilized PBMC RNA-seq data obtained from the plasma of another 11 healthy donors to examine the specific expression patterns of these genes. Among 94 CVD causal genes, 39 were enriched in one or more cell types (FDR adjust P < 0.05 and $\log FC > 1.5$, Supplementary Table 9), include CD4 T cells, CD14+ monocytes, Platelet, Natural killer cell and other monocyte. A total of 21 genes were highly expressed in CD14+ monocytes, and half of these genes (11 out of 21) were also found to be stably expressed in CD14+ monocytes through stability analysis.

Drug repurposing analyses identified potential therapeutic targets for CVD

To investigate the potential drug target genes, we construct a gene-drug-disease network (Fig4 D). The results showed that 25 of the 94 proteins are the targets of 53 drugs with completed or currently undergoing clinical trials (Supplementary Table 10). 14 drugs have already been used for treating circulatory system disorders. For example, Drotrecogin alfa targeting *F2*, *PROCR* and *PROS1* are currently one of the efficacious treatments for managing cerebrovascular ischemic events³⁸. The rest 39 drugs for treating diseases from other systems might be considered in further drug repurposing research. For example, Menadione targeting PROC are currently used for treating vitamin K deficiency and prostate cancer.

Discussion

In this study, we integrated data from 26 CVD GWAS along with three large-scale human plasma protein datasets to conduct a comprehensive PWAS analysis. Collectively, we identified 186 significant independent protein-disease association pairs, involving 94 unique proteins associated with CVD. Among these proteins, 41 proteins are novel proteins not implicated in original GWAS. We also elucidated potential biological mechanisms underlying CVD and provided potential new targets for CVD drug development. The PWAS analysis identified 96 genes that are consistent with being causal in CVD, including 41 novel genes not implicated in original GWAS. For example, PROC was newly found to be associated with venous thromboembolism. PROC is a vitamin Kdependent enzyme that plays a crucial role in regulating human thrombosis and hemostasis³⁹. Consist with our results, previous studies have demonstrated that reduced PROC levels in plasma can be used as a marker of increased risk of venous thrombosis 40, 41. In the PPI network, we also demonstrated that PROC, together with coagulation factors such as F2 and F10, forms a venous-related network. Longitudinal stability analysis showed that this protein is stably expressed in blood plasma. Currently, two drugs (Menadione and Cupric Chloride) targeting PROC have passed clinical trials for the treatment of conditions such as fungal infections, prostate cancer, and vitamin K deficiency⁴². Further studies are needed to explore the potential of these drugs for treating venous thromboembolism.

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

91.49% (86/94) of the identified proteins are category-specific, suggesting that the underlying pathogenesis mechanisms of the three disease categories are different. Only two proteins (ABO and PROCR) were associated with diseases in all three CVD categories. ABO was found to be positively associated with multiple cardiovascular diseases. Consistently, epidemiological studies have reported that ABO is associated with a wide range of diseases, including cardiovascular ailments, malignancies, and infectious conditions^{43,44}. PROCR is positively associated with venous disorders but negatively associated with stroke and coronary artery disease. PROCR is a receptor for activated protein C, which is a serine protease activated by and involved in the blood coagulation pathway. Consistent with our results, GWAS studies have shown that the minor G allele of rs867186 at this gene is correlated with a higher risk of venous thromboembolism^{45, 46} but a lower risk of CAD^{47, 48}. A previous study³⁰ has shown that PROCR linked to CAD through anti-inflammatory mechanisms and to VTE through pro-thrombotic mechanisms. The longitudinal stability analysis showed that 37 of the 44 detected proteins (84.09%) exhibit stable expression in plasma, suggesting that they might serve as potential markers of disease status. In addition, PBMC scRNA data analysis identified 24 genes exhibited stable expression in at least one cell type and 23 of the 24 genes stably expressed in CD14+ monocytes, highlighting the important role of CD14+ monocytes in CVD development. Consistently, previous studies have associated increased frequency of the CD14+ monocytes clinical CVD events and plaque vulnerability^{49, 50}.

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

Monocyte density of CD14 was found to be higher in patients with moderate □ severe heart failure in comparison with normal or mild LV impairment ^{51, 52}. These results suggested that CD14+ monocytes might be used as markers for CVD. Our study has several limitations. First, since the current available proteomics and GWAS are mainly derived from European populations, our results are mainly applicable to the European population. Second, we focused on cis-regulatory elements when constructing models to assess protein influences. This is a common choice for current researchers, because the current sample size of proteomics may not be sufficient to detect the trans effect. With larger scale data available in future, models considering both cis and trans effects can be constructed. In summary, using the largest available proteomics data from UKB-PPP projects (a total of 1,715 inheritable proteins from 53,202 individuals), we performed a PWAS study for 26 CVDs. We identified 94 genes that contribute to CVD pathogenesis through modulating their plasma protein abundance. These genes may serve as potential targets for future mechanistic and therapeutic studies aimed at finding effective treatments for CVD. Methods Human plasma proteomic and genetic data in UKB. We generated the human blood plasma proteome models from 53,022 participants of

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

European ancestry of the UKB-PPP. The sample was selected in two batches from Consortium members and UK Biobank cohort and the proteomic profiling was performed using standard Olink proteomics pipeline using Proximity Extension Assay ²⁰. antibodies matched to unique complementary oligonucleotides, which were bound to their respective target proteins, underwent quantification through next-generation sequencing. Following rigorous quality control measures, the normalized protein expression (NPX) values were computed using the Inter-Plate Control method. This NPX score effectively served as a quantitative measure of protein abundance in our samples. Genotype data matching the protein dataset underwent genotyping, imputation, and quality control steps as detailed in previous work ⁵³. This included sex discrepancy, sex chromosome aneuploidy, and heterozygosity checks, with imputed variants filtered for INFO scores >0.7. All chromosomal positions were updated to the hg38 assembly using LiftOver ⁵⁴. Genotyping quality control was executed using PLINK2.0 software⁵⁵. Participants exhibiting over 5% missing genotypic data were removed from consideration. Moreover, variants displaying deviations from the Hardy-Weinberg equilibrium (with p-values less than $1x10^{-8}$), a genotype missing rate exceeding 5%, a minor allele frequency below 1%, or those not classified as SNPs, were also excluded from the analysis. Following the preprocessing of both genotype and protein datasets, we adopted the FUSION software to train the proteome model and we only consider the subset comprising 1,190,321 SNPs from the HapMap3 project ⁵⁶. SNPs situated up to 500 kb

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

away from either end of genes were defined as cis-SNPs. The model further incorporated adjustments for protein expression based on gender and age as covariates to refine the association analysis and account for potential confounding variables. CVD GWAS summary association statistics Our GWAS data mainly comes from the GWAS catalog ^{22 25 21, 23, 24, 26} and FinnGen ⁵⁷ database. In accordance with the ICD-10 standard of circulatory disorders, we selected GWAS studies involving a minimum of 5,000 cases. When multiple studies of the same condition were identified, we opted for those with the largest sample sizes. This stringent selection procedure resulted in a final cohort of 26 unique GWAS for our investigation. Based on the distinct pathophysiological mechanisms, we categorized the diseases into cardiac diseases, venous disease, and cerebrovascular disease. Statistical approach Proteome-wide association studies (PWAS). We used the standard processes in the FUSION software²⁹ to construct protein models and incorporate GWAS data for our PWAS analysis. After applying the previously outlined quality control measures to screen the sample and genotype data, we utilized GCTA software⁵⁸ to estimate the SNP-based heritability for individual proteins. To expedite calculations, a random subset of approximately 10,000 individuals was selected from the full cohort for each protein's heritability estimation. From the analysis of 2,923 proteins, 1,715 displayed

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

statistically significant heritability ($h^2 > 0$, p < 0.05). We then employed the FUSION software to estimate the impact of SNPs on protein abundance using multiple predictive models (top1, lasso, enet) ²⁹ and select the most predictive model as the final predictor. Finally, we obtained a total of 1,715 distinct protein models encoded by different genes and we applied the Bonferroni correction for multiple testing. Consequently, proteins with a P-value threshold of 2.92×10⁻⁵ (0.05/1,715) were deemed statistically significant in our discovery PWAS analysis. We then performed the replication PWAS analysis in two other publicly available data sets. The modeling methodologies for these datasets have been documented in prior research, the Atherosclerosis Risk in Communities (ARIC) study dataset included 4,483 protein measurements from 7,213 European participants ²⁷, while the INTERVAL study retained information on 3,170 proteins for 3,301 individuals ²⁸. Subsequent to the heritability filtering phase, an ensemble of 2,379 proteins (1,348 in ARIC and 1,031 in INTERVAL) was selected for incorporation into our replication verification. Causal analysis. We adopted two independent frameworks to rigorously ascertain the causal inference of the proteins implicated in our PWAS findings. For the Bayesian colocalization analysis ¹⁶, we employed the COLOC module embedded within the FUSION software suite. The COLOC tool operates by estimating the posterior probability indicating that the same causal variant underlies both GWAS and pQTL.

Within the colocalization analysis framework, a comprehensive set of five hypotheses (H0 through H4) are scrutinized. Notably, hypothesis H4 posits the existence of a SNP that acts as a shared causal driver for both pQTL and GWAS. In our study, we defined causality for proteins identified through the COLOC analysis as those exhibiting a posterior probability for Hypothesis H4 exceeding 0.7. We subsequently employed the SMR ¹⁵ approach to further validate the causal relationships inferred from the PWAS and GWAS. For this SMR analysis, we leveraged recently published pQTL data ²⁰, which were derived from UKB-PPP study, complemented by independently obtained GWAS data ^{21-24, 26, 57} on cardiovascular disease, which were also considered in our PWAS. Our determination of significant causal relationships relied on an adjusted P <0.05 for the SMR analysis and the unadjusted P>0.05 from the HEIDI test.

PPI and GO enrichment

For the investigation of causal genes implicated in three diseases, we employed the STRING ³³ database to perform an extensive network analysis. The Markov cluster (MCL) algorithm was used with the following parameters: inflation parameter—1.5. Subsequently, the derived network was refined and visually optimized utilizing Cytoscape ⁵⁹ software. In this visualization, node size corresponds to the degree of connectivity for each gene, indicative of its interaction frequency within the network, while distinct colors denote different gene categories, facilitating categorical distinction and interpretation. Additionally, we conducted functional enrichment analysis for causal genes pertinent in three categories diseases using the WebGestalt ³²

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

online platform, focusing on the GO BP pathways. We select the pathways with P < 0.05 (with FDR adjusted) and number of overlap genes > 3 as the significant result. Longitudinal Data Stability Analysis We conducted a longitudinal analysis utilizing the data set GSE190992 from the Gene Expression Omnibus (GEO) database ⁶⁰. Specific details regarding the data collection methodology and information have been reported in detail in a previous publication. The data encompass proteomics measurements over a 10-week period for 6 healthy donors, as well as single-cell data collected over a six-week period for 4 of these donors. For each donor, we calculated the coefficient of variation (CV) for each gene at both the proteome and single-cell levels as a measure of stability (CV = standard deviation / mean × 100%). We selected thresholds of 10% as criteria for stable gene expression in proteome data and single-cell data, respectively. These genes that exhibit stable expression in plasma, along with the associated cell types, can be considered as more reliable biomarkers for early screening and prediction of CVD. Cell-type specific expression of the CVD causal genes We utilized scRNA-seq data from 11 healthy donors sourced from the GEO database (GSE244515). During the preprocessing phase, we filtered out cells that expressed less than 200 genes or had a mitochondrial gene content exceeding 15%. For cell type annotation, we normalized the count matrices using the LogNormalize method with a scaling factor of 10,000, which also helped in identifying variable features. To align

datasets from different samples and mitigate batch effects, we applied the Harmony integration method. These procedures were carried out using Seurat package version 4.4.0 within the R environment. After quality control and normalization, the data comprised a total of 27,484 genes across 371,086 cells. For the 94 CVD causal genes, we used the Wilcoxon rank sum test to compare the expression levels between the cells of interest and other cells. We applied FDR correction to the P values derived from the multiple tests, with the total number of tests set to 27,484 genes. Finally, we retained the significant results of FDR P value < 0.05 and logFC > 1.5, and thought that the expression was specific expression in cells.

Mouse genome informatics and Drug analysis

MGI database 34 serves as a global repository for murine research, offering a comprehensive integration of genetic, genomic, and biological information. This platform fosters investigations into human health and disease by facilitating insights garnered from mouse models and we demonstrated many of the gene deletion mouse models exhibit phenotypes associated with circulatory system disease. We enriched the mouse phenotype using the Fisher's exact test method, and retained phenotypes with more than three overlap genes, P < 0.05 (with FDR adjusted) and OR > 1. Furthermore, we constructed a gene-drug-disease interaction network by integrating gene-drug associations from the DrugBank 61 database and drug-disease relationships from the Therapeutic Target Database (TTD) 62 . Our network focused exclusively on drugs with approved clinical efficacy and excluding those with discontinued

470 development at any stage. 471 472 Code availability 473 All software and datasets in our study are publicly available online. 474 475 Acknowledgments 476 This research has been conducted using the UK biobank resource under application 477 number 46387. 478 479 **Funding** 480 This work was supported by the National Natural Science Foundation of China 481 (32370653, and 82372458); Innovation Capability Support Program of Shaanxi 482 Province (2022TD-44); Key Research and Development Project of Shaanxi Province 483 (2022GXLH-01-22), and the Fundamental Research Funds for the Central 484 Universities. This study was also supported by the High-Performance Computing 485 Platform and Instrument Analysis Center of Xi'an Jiaotong University. 486 487 **Data and Resource Availability** 488 The GWAS summary data of CVD we used in this article were available from GWAS 489 catalog (https://www.ebi.ac.uk/gwas/downloads/summary-statistics) and FinnGen 490 study (https://finngen.gitbook.io/documentation/data-download). Download links for 491 all datasets are provided in Table S1.

493

494

495

496

497

498

499

500

501

502

503

504

505

506

Author Contributions J.-H.W. and S.-S.D. designed this project. J.-H.W., A.-H.W., and C.-R.W. conducted the computational work. J.-H.W. wrote the manuscript. S.-S.D. and A-H.W. revised the manuscript. J.-H.W., H-A.W. and S.-S.D. summarized the tables and figures. R.-J.Z., W.S., H.W., K.Y, T.-P.Z., X.Y. M. and S-S.L. collected the public data. Y.G. and T.-L.Y. supported and supervised this project. Ethical approval and consent to participate All datasets were publicly available, and ethical approval and informed consent were acquired for all original studies. **Competing interests** The authors declare that they have no conflict of interest.

References

- 508 1. Townsend N, Kazakiewicz D, Lucy Wright F, et al. Epidemiology of cardiovascular
- 509 disease in Europe. Nat Rev Cardiol. Feb 2022;19(2):133-143. doi:10.1038/s41569-021-
- 510 00607-3

507

- 511 2. Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282
- 512 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the
- 513 Global Burden of Disease Study 2017. Lancet. Nov 10 2018;392(10159):1736-1788.
- 514 doi:10.1016/S0140-6736(18)32203-7
- 515 3. Holmes MV, Richardson TG, Ference BA, Davies NM, Davey Smith G. Integrating
- 516 genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug
- 517 development. Nat Rev Cardiol. Jun 2021;18(6):435-453. doi:10.1038/s41569-020-00493-1
- 518 4. Ward NC, Watts GF, Eckel RH. Statin Toxicity. *Circ Res.* Jan 18 2019;124(2):328-350.
- 519 doi:10.1161/CIRCRESAHA.118.312782
- 520 5. Li Y, Li Z, Ren Y, et al. Mitochondrial-derived peptides in cardiovascular disease: Novel
- 521 insights and therapeutic opportunities. J Adv Res. Nov 24
- 522 2023; doi:10.1016/j.jare.2023.11.018
- 523 6. Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic
- 524 and transcriptomic analyses. Nature Reviews Genetics. 2012;13(4):227-232.
- 525 doi:10.1038/nrg3185
- 526 7. Yao P, Iona A, Pozarickij A, et al. Proteomic Analyses in Diverse Populations Improved
- 527 Risk Prediction and Identified New Drug Targets for Type 2 Diabetes. *Diabetes Care*. Jun 1
- 528 2024;47(6):1012-1019. doi:10.2337/dc23-2145

- 529 8. Lindsey ML, Mayr M, Gomes AV, et al. Transformative Impact of Proteomics on
- 530 Cardiovascular Health and Disease. Circulation. 2015;132(9):852-872.
- 531 doi:10.1161/cir.00000000000000226
- 532 9. Wik L, Nordberg N, Broberg J, et al. Proximity Extension Assay in Combination with
- 533 Next-Generation Sequencing for High-throughput Proteome-wide Analysis. *Mol Cell*
- 534 *Proteomics*. 2021;20:100168. doi:10.1016/j.mcpro.2021.100168
- 535 10. Haslam DE, Li J, Dillon ST, et al. Stability and reproducibility of proteomic profiles in
- epidemiological studies: comparing the Olink and SOMAscan platforms. Proteomics. Jul
- 537 2022;22(13-14):e2100170. doi:10.1002/pmic.202100170
- 538 11. Wang R-S, Maron BA, Loscalzo J. Multiomics Network Medicine Approaches to
- 539 Precision Medicine and Therapeutics in Cardiovascular Diseases. Arteriosclerosis,
- 540 Thrombosis, and Vascular Biology. 2023;43(4):493-503. doi:10.1161/atvbaha.122.318731
- 541 12. Brandes N, Linial N, Linial M. PWAS: proteome-wide association study-linking genes and
- 542 phenotypes by functional variation in proteins. *Genome Biol.* Jul 14 2020;21(1):173.
- 543 doi:10.1186/s13059-020-02089-x
- 544 13. Wingo AP, Liu Y, Gerasimov ES, et al. Integrating human brain proteomes with genome-
- 545 wide association data implicates new proteins in Alzheimer's disease pathogenesis. Nat
- 546 *Genet.* Feb 2021;53(2):143-146. doi:10.1038/s41588-020-00773-z
- 547 14. Wingo TS, Liu Y, Gerasimov ES, et al. Brain proteome-wide association study implicates
- 548 novel proteins in depression pathogenesis. Nat Neurosci. Jun 2021;24(6):810-817.
- 549 doi:10.1038/s41593-021-00832-6
- 550 15. Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies

- 551 predicts complex trait gene targets. *Nat Genet.* May 2016;48(5):481-7. doi:10.1038/ng.3538
- 552 16. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation
- 553 between pairs of genetic association studies using summary statistics. PLoS Genet. May
- 554 2014; 10(5):e1004383. doi:10.1371/journal.pgen.1004383
- 555 17. Li SJ, Shi JJ, Mao CY, et al. Identifying causal genes for migraine by integrating the
- 556 proteome and transcriptome. *J Headache Pain*. Aug 17 2023;24(1):111. doi:10.1186/s10194-
- 557 023-01649-3
- 558 18. Phillips B, Western D, Wang L, et al. Proteome wide association studies of LRRK2
- 559 variants identify novel causal and druggable proteins for Parkinson's disease. NPJ
- 560 Parkinsons Dis. Jul 8 2023;9(1):107. doi:10.1038/s41531-023-00555-4
- 561 19. Wu BS, Chen SF, Huang SY, et al. Identifying causal genes for stroke via integrating the
- 562 proteome and transcriptome from brain and blood. J Transl Med. Apr 21 2022;20(1):181.
- 563 doi:10.1186/s12967-022-03377-9
- 564 20. Sun BB, Chiou J, Traylor M, et al. Plasma proteomic associations with genetics and
- 565 health in the UK Biobank. *Nature*. Oct 2023;622(7982):329-338. doi:10.1038/s41586-023-
- 566 06592-6
- 567 21. Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-driven genomic discovery
- 568 yields new insight into atrial fibrillation biology. Nat Genet. Sep 2018;50(9):1234-1239.
- 569 doi:10.1038/s41588-018-0171-3
- 570 22. Shah S, Henry A, Roselli C, et al. Genome-wide association and Mendelian
- randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun.
- 572 Jan 9 2020;11(1):163. doi:10.1038/s41467-019-13690-5

- 573 23. Donertas HM, Fabian DK, Valenzuela MF, Partridge L, Thornton JM. Common genetic
- 574 associations between age-related diseases. Nat Aging. Apr 2021;1(4):400-412.
- 575 doi:10.1038/s43587-021-00051-5
- 576 24. Hartiala JA, Han Y, Jia Q, et al. Genome-wide analysis identifies novel susceptibility loci
- 577 for myocardial infarction. Eur Heart J. Mar 1 2021;42(9):919-933.
- 578 doi:10.1093/eurheartj/ehaa1040
- 579 25. Mishra A, Malik R, Hachiya T, et al. Stroke genetics informs drug discovery and risk
- 580 prediction across ancestries. *Nature*. Nov 2022;611(7934):115-123. doi:10.1038/s41586-022-
- 581 05165-3
- 582 26. Sollis E, Mosaku A, Abid A, et al. The NHGRI-EBI GWAS Catalog: knowledgebase and
- 583 deposition resource. Nucleic Acids Res. Jan 6 2023;51(D1):D977-D985.
- 584 doi:10.1093/nar/gkac1010
- 585 27. Zhang J, Dutta D, Kottgen A, et al. Plasma proteome analyses in individuals of European
- 586 and African ancestry identify cis-pQTLs and models for proteome-wide association studies.
- 587 Nat Genet. May 2022;54(5):593-602. doi:10.1038/s41588-022-01051-w
- 588 28. Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome.
- 589 *Nature*. Jun 2018;558(7708):73-79. doi:10.1038/s41586-018-0175-2
- 590 29. Gusev A, Ko A, Shi H, et al. Integrative approaches for large-scale transcriptome-wide
- 591 association studies. *Nat Genet*. Mar 2016;48(3):245-52. doi:10.1038/ng.3506
- 592 30. Stacey D, Chen L, Stanczyk PJ, et al. Elucidating mechanisms of genetic cross-disease
- associations at the PROCR vascular disease locus. Nat Commun. Mar 9 2022;13(1):1222.
- 594 doi:10.1038/s41467-022-28729-3

- 595 31. Thomas PD, Ebert D, Muruganujan A, Mushayahama T, Albou LP, Mi H. PANTHER:
- 596 Making genome-scale phylogenetics accessible to all. Protein Science. 2021;31(1):8-22.
- 597 doi:10.1002/pro.4218
- 598 32. Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit
- 599 with revamped UIs and APIs. Nucleic Acids Res. Jul 2 2019;47(W1):W199-W205.
- 600 doi:10.1093/nar/gkz401
- 601 33. Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein-
- 602 protein association networks and functional enrichment analyses for any sequenced genome
- 603 of interest. Nucleic Acids Res. Jan 6 2023;51(D1):D638-D646. doi:10.1093/nar/gkac1000
- 604 34. Blake JA, Baldarelli R, Kadin JA, et al. Mouse Genome Database (MGD):
- 605 Knowledgebase for mouse-human comparative biology. Nucleic Acids Research.
- 606 2021;49(D1):D981-D987. doi:10.1093/nar/gkaa1083
- 35. Jaipersad AS, Lip GY, Silverman S, Shantsila E. The role of monocytes in angiogenesis
- 608 and atherosclerosis. *J Am Coll Cardiol*. Jan 7-14 2014;63(1):1-11.
- 609 doi:10.1016/j.jacc.2013.09.019
- 610 36. Tahir S, Steffens S. Nonclassical monocytes in cardiovascular physiology and disease.
- 611 Am J Physiol Cell Physiol. May 1 2021;320(5):C761-C770. doi:10.1152/ajpcell.00326.2020
- 612 37. Ruder AV, Wetzels SMW, Temmerman L, Biessen EAL, Goossens P. Monocyte
- 613 heterogeneity in cardiovascular disease. Cardiovasc Res. Sep 5 2023;119(11):2033-2045.
- 614 doi:10.1093/cvr/cvad069
- 615 38. Southan C, Sharman JL, Benson HE, et al. The IUPHAR/BPS Guide to
- 616 PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein

- 617 targets and 6000 ligands. Nucleic Acids Res. Jan 4 2016;44(D1):D1054-68.
- 618 doi:10.1093/nar/gkv1037
- 619 39. Dinarvand P, Moser KA. Protein C Deficiency. Arch Pathol Lab Med. Oct
- 620 2019;143(10):1281-1285. doi:10.5858/arpa.2017-0403-RS
- 621 40. Tang W, Stimson MR, Basu S, et al. Burden of rare exome sequence variants in PROC
- 622 gene is associated with venous thromboembolism: a population-based study. J Thromb
- 623 *Haemost*. Feb 2020;18(2):445-453. doi:10.1111/jth.14676
- 624 41. Manderstedt E, Lind-Hallden C, Hallden C, et al. Classic Thrombophilias and Thrombotic
- Risk Among Middle-Aged and Older Adults: A Population-Based Cohort Study. J Am Heart
- 626 Assoc. Feb 15 2022;11(4):e023018. doi:10.1161/JAHA.121.023018
- 627 42. Kovács KB, Pataki I, Bárdos H, et al. Molecular characterization of p. Asp77Gly and the
- 628 novel p. Ala163Val and p. Ala163Glu mutations causing protein C deficiency. Thrombosis
- 629 research. 2015;135(4):718-726.
- 630 43. Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a
- 631 systematic review and meta-analysis. J Thromb Haemost. Jan 2008;6(1):62-9.
- 632 doi:10.1111/j.1538-7836.2007.02818.x
- 633 44. Li S, Schooling CM. A phenome-wide association study of ABO blood groups. BMC Med.
- 634 Nov 17 2020;18(1):334. doi:10.1186/s12916-020-01795-4
- 635 45. Dennis J, Johnson CY, Adediran AS, et al. The endothelial protein C receptor (PROCR)
- 636 Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-
- analysis of evidence from observational studies. *Blood*. Mar 8 2012;119(10):2392-400.
- 638 doi:10.1182/blood-2011-10-383448

- 639 46. Medina P, Navarro S, Bonet E, et al. Functional analysis of two haplotypes of the human
- 640 endothelial protein C receptor gene. Arterioscler Thromb Vasc Biol. Mar 2014;34(3):684-90.
- 641 doi:10.1161/ATVBAHA.113.302518
- 642 47. Howson JMM, Zhao W, Barnes DR, et al. Fifteen new risk loci for coronary artery
- 643 disease highlight arterial-wall-specific mechanisms. Nat Genet. Jul 2017;49(7):1113-1119.
- 644 doi:10.1038/ng.3874
- 645 48. van der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides an
- 646 Expanded View on the Genetic Architecture of Coronary Artery Disease. Circ Res. Feb 2
- 647 2018;122(3):433-443. doi:10.1161/CIRCRESAHA.117.312086
- 648 49. Kashiwagi M, Imanishi T, Tsujioka H, et al. Association of monocyte subsets with
- 649 vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector
- 650 computed tomography in patients with stable angina pectoris. Atherosclerosis. Sep.
- 651 2010;212(1):171-6. doi:10.1016/j.atherosclerosis.2010.05.004
- 652 50. Tapp LD, Shantsila E, Wrigley BJ, Pamukcu B, Lip GY. The CD14++CD16+ monocyte
- subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction.
- 654 J Thromb Haemost. Jul 2012;10(7):1231-41. doi:10.1111/j.1538-7836.2011.04603.x
- 655 51. Anker SD, Egerer Kr Fau Volk HD, Volk Hd Fau Kox WJ, Kox Wj Fau Poole-Wilson
- 656 PA, Poole-Wilson Pa Fau Coats AJ, Coats AJ. Elevated soluble CD14 receptors and altered
- 657 cytokines in chronic heart failure. (0002-9149 (Print))
- 658 52. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart
- 659 failure: a prospective cohort study. Lancet. May 29 1999;353(9167):1838-42.
- 660 doi:10.1016/S0140-6736(98)09286-1

- 661 53. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep
- 662 phenotyping and genomic data. *Nature*. Oct 2018;562(7726):203-209. doi:10.1038/s41586-
- 663 018-0579-z
- 664 54. Hinrichs AS, Karolchik D, Baertsch R, et al. The UCSC Genome Browser Database:
- 665 update 2006. Nucleic Acids Res. Jan 1 2006;34(Database issue):D590-8.
- 666 doi:10.1093/nar/gkj144
- 55. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
- 668 PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.
- 669 doi:10.1186/s13742-015-0047-8
- 670 56. International HapMap C, Altshuler DM, Gibbs RA, et al. Integrating common and rare
- 671 genetic variation in diverse human populations. Nature. Sep 2 2010;467(7311):52-8.
- 672 doi:10.1038/nature09298
- 673 57. Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-
- 674 phenotyped isolated population. *Nature*. Jan 2023;613(7944):508-518. doi:10.1038/s41586-
- 675 022-05473-8
- 676 58. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait
- 677 analysis. Am J Hum Genet. Jan 7 2011;88(1):76-82. doi:10.1016/j.ajhg.2010.11.011
- 678 59. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated
- models of biomolecular interaction networks. Genome Res. Nov 2003;13(11):2498-504.
- 680 doi:10.1101/gr.1239303
- 681 60. Vasaikar SV, Savage AK, Gong Q, et al. A comprehensive platform for analyzing
- 682 longitudinal multi-omics data. Nat Commun. Mar 27 2023;14(1):1684. doi:10.1038/s41467-

683 023-37432-w 684 61. Knox C, Wilson M, Klinger CM, et al. DrugBank 6.0: the DrugBank Knowledgebase for 685 2024. Nucleic Acids Res. Jan 5 2024;52(D1):D1265-D1275. doi:10.1093/nar/gkad976 686 62. Zhou Y, Zhang Y, Zhao D, et al. TTD: Therapeutic Target Database describing target 687 5 2024;52(D1):D1465-D1477. druggability information. Nucleic Acids Res. Jan 688 doi:10.1093/nar/gkad751 689 690

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

Figure Legends Figure 1. Workflow of the current study. We collected proteomics data from three different sources: UKB, ARIC and INTERVAL. GWAS summary data for 26 CVDs spanning 3 categories (16 cardiac diseases, 5 venous diseases, 5 cerebrovascular diseases, up to 1,308,460 individuals) were included. We performed PWAS with proteomics data from the three projects followed by Mendelian randomization and colocalization analysis. Functional annotation of the genes identified by PWAS was finally performed. Figure 2. Result of the PWAS **A.** Manhattan plot for the PWAS of CVD. Each dot represents the correlation between a disease and a gene, with the x-axis indicating genomic location and the y-axis showing -log₁₀(P). The gray horizontal line represents the Bonferroni-corrected significant threshold, $P < 2.92 \times 10^{-5}$. The significant results of the three categories diseases are shown in red, green, blue, respectively. The labeled genes are the most significant results on each chromosome **B.** The number of significant genes in PWAS for 26 CVD diseases. Different colors represent different disease categories. 27 jointly significant genes dropped by conditional analysis (gray). C. Regional association of PWAS hits in conditional analysis for heart failure. Conditionally significant proteins are CELSR2, GSTM1, SPINK8, DAG1, HYAL1, FABP2, ACYP1, FES, GSTT2B and SUSD2. Top panel in each plot highlights the

713 marginally associated PWAS genes (blue) and the jointly significant genes (green). 714 Bottom panel shows a regional Manhattan plot of the data before (grey) and after 715 (blue) conditioning on the predicted expression of the green genes. Chr: chromosome. 716 717 Figure 3. Results for the causal genes. 718 A. The heatmap presents whole PWAS results for 94 genes passing causality tests and 719 color depth reflects the association direction and magnitude. Genes identified in 720 replication PWAS are represented by circles in the heatmap. Causal genes are labeled "*" and the novel gene with no significant variant $(P < 5 \times 10^{-8})$ within ± 2 M window 721 722 of the gene range in GWAS results are labeled in red. 723 **B.** The Venn diagram illustrates the overlap of causal genes across three disease 724 categories. 725 C. The number of novel genes in different diseases. 726 D. The top Manhattan plot represents the pQTL and the GWAS results within the 727 PROC genomic region for venous thromboembolism. The bottom Manhattan plot 728 represents the pQTL and the GWAS results within the FN1 genomic region for 729 coronary heart disease and coronary atherosclerosis. 730 731 Figure 4. Function annotation of the identified genes 732 **A.** The significant enriched Gene Ontology (GO) biological process (BP) terms of the 733 causal genes in different categories. The color of the bar represents the biological 734 function category to which the pathway belongs. Immunity/inflammation (light coral),

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

lipid-related process (faint yellow), vessel/blood-related process (purple) and other (gray). **B.** The network constructed with identified causal genes. Lines represent a physical interaction, and line thickness is proportional to the interaction score. Genes associated with cardiac disease, venous disease and cerebrovascular disease are shown in red, green, and blue, respectively. Genes with more connections are shown Community include with larger size. 1 16 proteins associated with immunity/inflammation. Community 2 include 6 proteins associated with lipid-related process. Community 3 include 6 proteins associated with vessel/blood-related process, especially the formation of fibrin clot. C. The significant enrichment results of mouse phenotypes of the causal genes in different categories. The color of the bar represents the biological function category to which the pathway belongs. Immunity/inflammation (light coral), lipid-related process (faint yellow), vessel/blood-related process, (purple) and other (gray). D. Results of the longitudinal stability analysis at the protein level (left) and singlecell level (right). At the protein level, genes are classified as stable (blue) or variable (red) based on a coefficient of variation (CV) threshold of 10%. Among the 94 causal genes, 37 genes were identified as stable. The color blocks on the left indicate the relevant grouping of the genes in the PWAS results. At the single-cell level, the threshold is set at 10%, with gray representing samples with low average expression (average expression < 0.01 after normalization). 24 genes exhibit stable expression across 19 cell types. Different donors are indicated by different colors.


757 E. The constructed gene-drug-disease network of causal genes. The colors of the lines
 758 in the network signify the category of genes. ICD: International Classification of
 759 Diseases.
 760
 761

Table 1. Summary of the 34 replicable CVD causal genes.


Gene	replicated	causal	PHE
ABO	Both	Both	Pulmonary embolism
	Both	COLOC	Deep Venous Thrombosis, Venous Thromboembolism
	INTERVAL	Both	Large artery stroke
	INTERVAL	COLOC	Myocardial infarction, Any stroke, Cardioembolic stroke
ANGPTL3	ARIC	COLOC	Statin medication
ASPN	Both	Both	Venous Thromboembolism
CCDC134	Both	Both	Atrial fibrillation
CD4	INTERVAL	SMR	Coronary atherosclerosis
COL15A1	Both	SMR	Atrial fibrillation
COL6A3	Both	Both	Heart failure
CTSB	INTERVAL	COLOC	Calcific aortic valvular stenosis
DLK1	INTERVAL	COLOC	Diseases of veins
DUSP13	INTERVAL	Both	Atrial fibrillation
ECM1	ARIC	COLOC	Hypertension
EPHA2	Both	Both	Statin medication
	Both	Both	Pulmonary embolism
F10	Both	COLOC	Venous Thromboembolism
	ARIC	Both	Deep Venous Thrombosis, Diseases of veins, Any stroke, Cardioembolic stroke
F11	ARIC	COLOC	Venous Thromboembolism, Pulmonary embolism
	Both	Both	Venous Thromboembolism, Pulmonary embolism
F2	Both	SMR	Deep Venous Thrombosis, Diseases of veins
FABP2	ARIC	SMR	Hypertension, Heart failure, Coronary revascularization
	ARIC	Both	Heart failure, Coronary Heart Disease, Angina pectoris
FN1			Myocardial infarction, Coronary atherosclerosis, Coronary revascularization,
	ARIC	COLOC	Coronary artery bypass grafting
GAS6	ARIC	COLOC	Statin medication
GSTT2B	INTERVAL	SMR	Heart failure
IL1RN	Both	SMR	Myocardial infarction
IL6R	Both	Both	Aortic aneurysm, Coronary Heart Disease, Coronary atherosclerosis, Angina
			pectoris, Coronary angioplasty
	Both	COLOC	Coronary revascularization, Coronary artery bypass grafting
	Both	SMR	Atrial fibrillation, Heart failure
INHBB	ARIC	Both	Coronary artery bypass grafting
	Both	COLOC	Statin medication
INHBC	ARIC	Both	Heart failure
ITIH3	ARIC	SMR	Heart failure
KLB	ARIC	SMR	Statin medication
LRIG1	ARIC	Both	Atrial fibrillation
MMP12	Both	Both	Any stroke
	Both	COLOC	Large artery stroke
NRP1	Both	SMR	Coronary Heart Disease
NUDT5	ARIC	SMR	Statin medication, Heart failure
PCSK9	ARIC	Both	Heart failure
	ARIC	COLOC	Statin medication, Myocardial infarction, Coronary Heart Disease, Coronary atherosclerosis, Angina pectoris, Coronary revascularization, Coronary angioplasty,
			Coronary artery bypass grafting, Valvular heart disease, Diseases of arteries and

			capillaries
	ARIC	SMR	Calcific aortic valvular stenosis
PROC	Both	Both	Venous Thromboembolism
THBS2	Both	COLOC	Diseases of veins, Varicose veins
	Both	SMR	Aortic aneurysm
TNFSF12	INTERVAL	Both	Atrial fibrillation
UROD	ARIC	Both	Diseases of veins

1. Discovery plasma proteome-wide association study (PWAS) analysis



2. Replication PWAS of CVD



3. Function verification of candidate causal genes

